# Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

> **NCT05160272** · PHASE2 · COMPLETED · sponsor: **The Deutsche Diabetes Forschungsgesellschaft e.V.** · enrollment: 38 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** AP-325
- **DRUG:** Placebo matching AP-325

## Key facts

- **NCT ID:** NCT05160272
- **Lead sponsor:** The Deutsche Diabetes Forschungsgesellschaft e.V.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-07
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05160272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05160272, "Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05160272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*